A study published in the European Journal of Pain explored the potential of transdermal cannabidiol (CBD) to reduce inflammation and pain in a rat model of arthritis. The researchers applied CBD gels at various doses (0.6 to 62.3 mg/day) to rats with induced arthritis over four days. Key findings included significant reductions in joint swelling, immune cell infiltration, and markers of inflammation in the spinal cord and surrounding tissues. The study also observed improvements in pain-related behaviors and activity levels without affecting higher brain functions.
Plasma concentration measurements showed consistent absorption at therapeutic doses, with the most effective results seen at 6.2 mg/day and 62 mg/day. Importantly, no adverse effects were reported, highlighting the safety and efficacy of CBD as a potential treatment for arthritis-related pain and inflammation.
This preclinical research supports the use of topical CBD as a non-invasive and side-effect-free alternative for managing chronic pain and inflammation, offering promise for future applications in humans.
References:
VIVO
Veterinary Cannabis Society
No comment yet, add your voice below!